肠道超声监测溃疡性结肠炎治疗反应:TRUST&UC研究
TRUST&UC是在德国42家炎症性肠病专科中心开展的前瞻性观察研究,连续纳入临床复发(Short Clinical Colitis Activity Index≥5)的直肠乙状结肠炎、左半结肠炎或全结肠炎患者,用经腹肠道超声评估病变肠壁厚度与血流。基线88.5%(n=224)患者降结肠或乙状结肠肠壁厚度增加,治疗2周内该比例显著下降并在6周、12周维持较低水平;12周时肠壁厚度正常化与临床应答高度相关。
要点
- 肠道超声可在常规诊疗中即时监测UC疾病活动与短期治疗反应
- 治疗2周内乙状结肠和降结肠肠壁增厚比例即显著下降并持续至12周
- 12周肠壁厚度正常化与症状应答高度相关,但单凭BWT预测疗效仍需未来研究验证
核心结论
- 肠道超声或适合在一般诊疗的点即时场景中用于监测UC病程和评估短期治疗反应。
- 研究结果提示单用肠壁厚度监测有可能预测治疗反应,但需未来研究验证。
研究设计与样本
- TRUST&UC为前瞻性观察研究,在德国42家代表不同诊疗级别的炎症性肠病专科中心开展。
- 连续纳入诊断为直肠乙状结肠炎、左半结肠炎或全结肠炎且当前临床复发(Short Clinical Colitis Activity Index≥5)的患者。
- 用双功/彩色多普勒超声评估受累肠壁区域疾病活动度和血管化。
主要发现
- 基线时88.5%(n=224)患者降结肠或乙状结肠肠壁厚度增加。
- 研究前2周内乙状结肠增厚比例由89.3%降至38.6%、降结肠由83.0%降至42.9%(p<0.001)。
- 第6周和第12周乙状结肠增厚比例分别为35.4%和32.0%,降结肠分别为43.4%和37.6%(p<0.001)。
- 治疗12周后肠壁厚度正常化与临床应答高度相关:正常化者中90.5%有症状应答,未正常化者中9.5%有症状应答(p<0.001)。
关键数值与推荐
- 临床复发定义为Short Clinical Colitis Activity Index≥5。
- BWT正常化与12周临床应答相关:90.5% vs 9.5%(p<0.001)。
临床怎么用
- 在一般诊疗的点即时场景可考虑用肠道超声监测UC病程和短期治疗反应。
- 可随访乙状结肠和降结肠肠壁厚度变化作为治疗反应的参考指标。
局限性
- 单用BWT预测治疗反应的假设尚需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prospective evaluation of intestinal ultrasound (IUS) for disease monitoring of patients with ulcerative colitis (UC) in routine medical practice. DESIGN: TRansabdominal Ultrasonography of the bowel in Subjects with IBD To monitor disease activity with UC (TRUST&UC) was a prospective, observational study at 42 German inflammatory bowel disease-specialised centres representing different care levels. Patients with a diagnosis of a proctosigmoiditis, left-sided colitis or pancolitis currently in clinical relapse (defined as Short Clinical Colitis Activity Index ≥5) were enrolled consecutively. Disease activity and vascularisation within the affected bowel wall areas were assessed by duplex/Colour Doppler ultrasonography. RESULTS: At baseline, 88.5% (n=224) of the patients had an increased bowel wall thickness (BWT) in the descending or sigmoid colon. Even within the first 2 weeks of the study, the percentage of patients with an increased BWT in the sigmoid or descending colon decreased significantly (sigmoid colon 89.3%-38.6%; descending colon 83.0%-42.9%; p<0.001 each) and remained low at week 6 and 12 (sigmoid colon 35.4% and 32.0%; descending colon 43.4% and 37.6%; p<0.001 each). Normalisation of BWT and clinical response after 12 weeks of treatment showed a high correlation (90.5% of patients with normalised BWT had symptomatic response vs 9.5% without symptomatic response; p<0.001). CONCLUSIONS: IUS may be preferred in general practice in a point-of-care setting for monitoring the disease course and for assessing short-term treatment response. Our findings give rise to the assumption that monitoring BWT alone has the potential to predict the therapeutic response, which has to be verified in future studies.
引用
- Maaser C, Petersen F, Helwig U, et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut. 2019. PMID: 31862811. doi:10.1136/gutjnl-2019-319451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。